Evidence map›Paper›PMID 36578621›Full record

ArticleProceedings (Baylor University. Medical Center)2023

Survival analysis of small cell carcinomas of the genitourinary system.

Bohdan Baralo, Michael Schneider, Ihor Baralo

Abstract read
In one paragraph

Article in Proceedings (Baylor University. Medical Center), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bohdan BaraloInternal Medicine, Mercy Catholic Medical Center, Darby, Pennsylvania.ORCID https://orcid.org/0000-0002-6185-3598
Michael SchneiderHematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.ORCID https://orcid.org/0000-0001-7270-5235
Ihor BaraloUrology, National Pirogov Memorial Medical University, Vinnytsia, Ukraine.ORCID https://orcid.org/0000-0003-3875-904X

Funding

CANCER RESEARCH TRAINING PROGRAMT32CA009615 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Gregory L Beatty, MICHAEL D HOGARTY · 1988 to 2026
$10.4M
NCI NIH HHS T32 CA009615
6 · The paper itself

Abstract

Due to low incidence, there are no large prospective studies or clinical trials for small cell carcinoma (SCC) of the genitourinary system (GU), and most data are extrapolated from SCC of the lung. Using the SEER database, we analyzed incidence trends, overall survival, and cancer-specific survival using the log-rank test. Analysis of variables was performed using the Cox proportional hazards regression model. The analysis showed that SCC of the bladder and prostate were the most common types of GU SCC, with 1836 and 606 cases, respectively. In 2018, the incidence of SCC of the bladder and prostate was twice that of 2010 (

Indexed as

Small cell carcinomasmall cell carcinoma of bladdersmall cell carcinoma of prostatesurvival analysis.

Identifiers

PMID36578621
PMCPMC9762741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.